Icariin and mesenchymal stem cells synergistically promote angiogenesis and neurogenesis after cerebral ischemia via PI3K and ERK1/2 pathways - 13/11/18
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
| pages | 7 |
| Iconographies | 7 |
| Vidéos | 0 |
| Autres | 0 |
Highlights |
• | ICA and MSCs increased VEGF and BDNF expression to a maximum. |
• | ICA and MSCs functioned through PI3K/Akt and ERK1/2 pathways. |
• | ICA and MSCs notably promoted angiogenesis and neurogenesis in vivo. |
• | ICA and MSCs had synergistic effect on cerebral ischemia treatment. |
Abstract |
Mesenchymal stem cells (MSCs) are one promising candidate for regenerative therapy of ischaemic stroke through transdifferetiation and paracrine actions. Icariin (ICA) has shown great potential in improving cell activity and VEGF, BDNF secretion in vitro. Whether they will synergistically improve therapy effect on cerebral ischemia is unknown. In this study, male SD rats were subjected to transient middle cerebral artery occlusion (MCAO) followed by reperfusion and ICA/MSC treatment. Results showed that ICA and MSCs combined treatment greatly reduced brain infarction volume, improved neurologic deficits of motor and somatosensory function and neurobehavioral outcomes. The combined therapy increased expression of VEGF and BDNF to a maximum through activating PI3K and ERK1/2 pathways in the hippocampus and frontal cortex in response to transient MCAO. They notably promoted angiogenesis and neurogenesis in vivo. Thus, ICA and MSCs combined treatment may represent a feasible approach for improving the beneficial effects of stem cell therapy for cerebral ischemia.
Le texte complet de cet article est disponible en PDF.Keywords : Icariin, Mesenchymal stem cell, Stroke, Cerebral ischemia, BDNF, VEGF, ERK1/2, PI3K, Angiogenesis, Neurogenesis
Plan
Vol 108
P. 663-669 - décembre 2018 Retour au numéro
Article précédent
- Transcription factor 7-like 2 controls matrix degradation through nuclear factor κB signaling and is repressed by microRNA-155 in nucleus pulposus cells
- Jianchao Sun, Junmin Hong, Siguo Sun, Xiaofei Wang, Yan Peng, Jie Zhou, Yingjie Huang, Shuangxing Li, Weijian Chen, Chunhai Li, Kang Xu, Wei Ye
- Design, synthesis, in vitro, in vivo and in silico pharmacological characterization of antidiabetic N-Boc-l-tyrosine-based compounds
- Miguel Ángel Herrera-Rueda, Hugo Tlahuext, Paolo Paoli, Abraham Giacoman-Martínez, Julio César Almanza-Pérez, Horacio Pérez-Sánchez, Abraham Gutiérrez-Hernández, Fabiola Chávez-Silva, Elix Alberto Dominguez-Mendoza, Samuel Estrada-Soto, Gabriel Navarrete-Vazquez
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?